vs
Side-by-side financial comparison of Dianthus Therapeutics, Inc. (DNTH) and SenesTech, Inc. (SNES). Click either name above to swap in a different company.
SenesTech, Inc. is the larger business by last-quarter revenue ($421.0K vs $284.0K, roughly 1.5× Dianthus Therapeutics, Inc.). SenesTech, Inc. runs the higher net margin — -428.5% vs -22687.3%, a 22258.8% gap on every dollar of revenue. On growth, SenesTech, Inc. posted the faster year-over-year revenue change (-16.0% vs -78.6%). SenesTech, Inc. produced more free cash flow last quarter ($-1.7M vs $-47.1M). Over the past eight quarters, SenesTech, Inc.'s revenue compounded faster (0.7% CAGR vs -44.6%).
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
SenesTech, Inc. is an agricultural biotechnology life-sciences company, specializing in fertility management as a form of pest control. The company's primary product, ContraPest is designed to make brown and black rats infertile. SenesTech is headquartered in Phoenix, Arizona.
DNTH vs SNES — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0K | $421.0K |
| Net Profit | $-64.4M | $-1.8M |
| Gross Margin | — | 55.3% |
| Operating Margin | -24486.3% | -446.8% |
| Net Margin | -22687.3% | -428.5% |
| Revenue YoY | -78.6% | -16.0% |
| Net Profit YoY | -126.6% | -43.7% |
| EPS (diluted) | $-1.53 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0K | $421.0K | ||
| Q3 25 | $396.0K | $690.0K | ||
| Q2 25 | — | $625.0K | ||
| Q1 25 | $1.2M | $485.0K | ||
| Q4 24 | $1.3M | $501.0K | ||
| Q3 24 | $2.2M | $482.0K | ||
| Q2 24 | $1.9M | $459.0K | ||
| Q1 24 | $874.0K | $415.0K |
| Q4 25 | $-64.4M | $-1.8M | ||
| Q3 25 | $-36.8M | $-1.3M | ||
| Q2 25 | — | $-1.6M | ||
| Q1 25 | $-29.5M | $-1.7M | ||
| Q4 24 | $-28.4M | $-1.3M | ||
| Q3 24 | $-25.2M | $-1.5M | ||
| Q2 24 | $-17.6M | $-1.6M | ||
| Q1 24 | $-13.7M | $-1.8M |
| Q4 25 | — | 55.3% | ||
| Q3 25 | — | 62.8% | ||
| Q2 25 | — | 65.4% | ||
| Q1 25 | — | 64.5% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | — | 65.4% | ||
| Q2 24 | — | 54.2% | ||
| Q1 24 | — | 32.5% |
| Q4 25 | -24486.3% | -446.8% | ||
| Q3 25 | -10173.7% | -195.2% | ||
| Q2 25 | — | -258.2% | ||
| Q1 25 | -2852.7% | -342.9% | ||
| Q4 24 | -2406.9% | -250.9% | ||
| Q3 24 | -1376.6% | -321.0% | ||
| Q2 24 | -1191.8% | -349.0% | ||
| Q1 24 | -2041.6% | -444.1% |
| Q4 25 | -22687.3% | -428.5% | ||
| Q3 25 | -9284.1% | -188.1% | ||
| Q2 25 | — | -258.6% | ||
| Q1 25 | -2537.5% | -343.3% | ||
| Q4 24 | -2144.8% | -250.5% | ||
| Q3 24 | -1159.0% | -313.9% | ||
| Q2 24 | -945.1% | -345.1% | ||
| Q1 24 | -1573.0% | -441.4% |
| Q4 25 | $-1.53 | $0.48 | ||
| Q3 25 | $-0.97 | $-0.28 | ||
| Q2 25 | — | $-0.87 | ||
| Q1 25 | $-0.82 | $-1.28 | ||
| Q4 24 | $-0.76 | $-0.15 | ||
| Q3 24 | $-0.74 | $-2.07 | ||
| Q2 24 | $-0.51 | $-3.08 | ||
| Q1 24 | $-0.54 | $-3.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $404.3M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $493.4M | $9.6M |
| Total Assets | $530.9M | $12.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $404.3M | $8.6M | ||
| Q3 25 | $402.6M | $10.2M | ||
| Q2 25 | — | $6.1M | ||
| Q1 25 | $263.2M | $1.7M | ||
| Q4 24 | $275.2M | $1.3M | ||
| Q3 24 | $281.1M | $2.5M | ||
| Q2 24 | $360.7M | $2.0M | ||
| Q1 24 | $377.0M | $3.6M |
| Q4 25 | $493.4M | $9.6M | ||
| Q3 25 | $546.5M | $11.3M | ||
| Q2 25 | — | $7.0M | ||
| Q1 25 | $328.6M | $2.9M | ||
| Q4 24 | $352.5M | $2.5M | ||
| Q3 24 | $337.9M | $3.7M | ||
| Q2 24 | $358.2M | $3.1M | ||
| Q1 24 | $372.7M | $4.6M |
| Q4 25 | $530.9M | $12.8M | ||
| Q3 25 | $577.4M | $14.6M | ||
| Q2 25 | — | $10.4M | ||
| Q1 25 | $348.6M | $3.6M | ||
| Q4 24 | $374.0M | $3.3M | ||
| Q3 24 | $354.2M | $4.4M | ||
| Q2 24 | $369.0M | $4.0M | ||
| Q1 24 | $382.5M | $5.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-47.0M | $-1.7M |
| Free Cash FlowOCF − Capex | $-47.1M | $-1.7M |
| FCF MarginFCF / Revenue | -16591.9% | -398.3% |
| Capex IntensityCapex / Revenue | 48.6% | 3.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-132.8M | $-5.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-47.0M | $-1.7M | ||
| Q3 25 | $-30.6M | $-1.4M | ||
| Q2 25 | — | $-1.1M | ||
| Q1 25 | $-27.6M | $-1.6M | ||
| Q4 24 | $-27.4M | $-1.2M | ||
| Q3 24 | $-21.3M | $-1.4M | ||
| Q2 24 | $-14.5M | $-1.6M | ||
| Q1 24 | $-14.9M | $-1.8M |
| Q4 25 | $-47.1M | $-1.7M | ||
| Q3 25 | $-30.6M | $-1.4M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | $-27.7M | $-1.6M | ||
| Q4 24 | $-27.5M | $-1.2M | ||
| Q3 24 | $-21.3M | $-1.4M | ||
| Q2 24 | $-14.5M | $-1.6M | ||
| Q1 24 | $-15.0M | $-1.8M |
| Q4 25 | -16591.9% | -398.3% | ||
| Q3 25 | -7717.2% | -205.9% | ||
| Q2 25 | — | -191.5% | ||
| Q1 25 | -2377.8% | -328.5% | ||
| Q4 24 | -2072.0% | -246.1% | ||
| Q3 24 | -980.3% | -296.1% | ||
| Q2 24 | -780.7% | -354.2% | ||
| Q1 24 | -1713.2% | -441.2% |
| Q4 25 | 48.6% | 3.1% | ||
| Q3 25 | 1.3% | 6.1% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | 2.1% | 7.4% | ||
| Q4 24 | 2.3% | 3.0% | ||
| Q3 24 | 1.2% | 5.8% | ||
| Q2 24 | 0.9% | 8.5% | ||
| Q1 24 | 3.7% | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
